Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

Sunnybrook Research Institute (Toronto, Ontario)

$932,818.00

Genetic Frontotemporal Dementia Initiative (GENFI) in Canada

FY 2013-14

Summary
There have been three major genes discovered that cause familial forms of frontotemporal dementia (FTD), a devastating group of disorders associated with personality and behavioural changes and/or language difficulties in those suffering. The impact to individuals and their families is huge because FTD affects those in the prime of their lives, often between the ages of 45 to 55. The gene abnormality predicts that an individual who harbours it will be at high risk of developing symptoms, but does not predict when this will occur and what features they will have. Therefore, it is critical that studies concentrate on developing powerful markers using brain imaging and genetics that can identify the earliest stages of disease before symptoms develop. It is hoped that novel drugs being developed can be used to eventually prevent the disease from starting in those at risk.
Program
Operating Grant
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
307260
Name
Masellis Mario
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Behavioural Sciences - B: Clinical Behavioural Sciences
Projecttitle
Genetic Frontotemporal Dementia Initiative (GENFI) in Canada
Programtype2
Operating Grants
Orgnameinp2
Sunnybrook Research Institute (Toronto, Ontario)
Cihramount2
$932,818
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Biomarkers; C9orf72; Cognition; Frontotemporal Dementia; Genomics; Mapt; Mri; Prgn
Abstract
There have been three major genes discovered that cause familial forms of frontotemporal dementia (FTD), a devastating group of disorders associated with personality and behavioural changes and/or language difficulties in those suffering. The impact to individuals and their families is huge because FTD affects those in the prime of their lives, often between the ages of 45 to 55. The gene abnormality predicts that an individual who harbours it will be at high risk of developing symptoms, but does not predict when this will occur and what features they will have. Therefore, it is critical that studies concentrate on developing powerful markers using brain imaging and genetics that can identify the earliest stages of disease before symptoms develop. It is hoped that novel drugs being developed can be used to eventually prevent the disease from starting in those at risk.
Competitiondate
201403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Masellis, Mario; Finger, Elizabeth
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $932,818~ $0~
Sunnybrook Research Institute (Toronto, Ontario) - $9… | Canada Spends